Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery
Related Posts
Powles TB, Grande E, Alimohamed N, Oliveira N, Sridhar SS, Drakaki A, Kanesvaran R, Loriot Y, Necchi A, Franco S, Jiang D, Apolinario K, Zhang[...]
Alkassis S, Glaspy JA, Bardia A. Revolutionizing breast cancer treatment: the promise of antibody-drug conjugates. Clin Adv Hematol Oncol. 2025 Jul-Aug;23(5):290-299. PMID: 40728347.
Black AC, Senofsky G. A Patient's Journey With Modern Melanoma Therapy. Cureus. 2025 Jun 26;17(6):e86811. doi: 10.7759/cureus.86811. PMID: 40718227; PMCID: PMC12296936.